Detalhe da pesquisa
1.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
; 387(2): 132-147, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660812
2.
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Haematologica
; 108(11): 2894-2912, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608773
3.
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma.
Cancer
; 128(10): 1996-2004, 2022 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35167125
4.
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 97(5): 562-573, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35132679
5.
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Lancet Oncol
; 22(1): 142-154, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33301738
6.
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Am J Hematol
; 96(12): 1595-1603, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34559902
7.
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
Haematologica
; 105(2): 468-477, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31221782
8.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 374(17): 1621-34, 2016 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27119237
9.
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Eur J Haematol
; 102(6): 494-503, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30943323
10.
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
Am J Hematol
; 94(11): 1244-1253, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31456261
11.
The proteasome and proteasome inhibitors in multiple myeloma.
Cancer Metastasis Rev
; 36(4): 561-584, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29196868
12.
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Br J Haematol
; 181(4): 433-446, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29748955
13.
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
Br J Haematol
; 182(2): 222-230, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29740809
14.
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Br J Haematol
; 180(6): 821-830, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29435979
15.
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
N Engl J Med
; 373(13): 1207-19, 2015 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26308596
16.
Ibrutinib in previously treated Waldenström's macroglobulinemia.
N Engl J Med
; 372(15): 1430-40, 2015 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25853747
17.
The power of proteasome inhibition in multiple myeloma.
Expert Rev Proteomics
; 15(12): 1033-1052, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30427223
18.
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
Blood
; 127(6): 681-95, 2016 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26631114
19.
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Blood
; 127(22): 2693-700, 2016 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27009059
20.
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Blood
; 128(14): 1821-1828, 2016 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27531679